{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:51:34Z","timestamp":1771692694353,"version":"3.50.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/rlu.0b013e3182816717","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T18:29:05Z","timestamp":1361471345000},"page":"231-236","source":"Crossref","is-referenced-by-count":6,"title":["Radioiodine Therapy for Graves Disease"],"prefix":"10.1097","volume":"38","author":[{"given":"Jos\u00e9","family":"Willegaignon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Tatit","family":"Sapienza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Alberto","family":"Buchpiguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210204","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/rpd\/nch013","article-title":"Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism.","volume":"108","author":"Jonsson","year":"2004","journal-title":"Radiat Prot Dosimetry"},{"key":"R2-1-20210204","first-page":"379","article-title":"Treatment of thyrotoxicosis.","volume":"48","author":"Iagaru","year":"2007","journal-title":"J Nucl Med"},{"key":"R3-1-20210204","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00259-001-0722-0","article-title":"Dose selection for radioiodine therapy of borderline hyperthyroid patients with multifocal and disseminated autonomy on the basis of 99mTc-pertechnetate thyroid uptake.","volume":"29","author":"Reinhardt","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-1-20210204","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/rpd\/ncm243","article-title":"Quantitative analysis of the factors responsible for over or under dose of 131I therapy patients of hyperthyroidism.","volume":"128","author":"Muhammad","year":"2008","journal-title":"Radiat Prot Dosimetry"},{"key":"R5-1-20210204","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00259-007-0471-9","article-title":"Clinical radionuclide therapy dosimetry: the quest for the Holy Gray.","volume":"34","author":"Flux","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-1-20210204","first-page":"228","article-title":"Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.","volume":"37","author":"Berg","year":"1996","journal-title":"J Nucl Med"},{"key":"R8-1-20210204","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1089\/cbr.2005.20.218","article-title":"Comparison of different thyroid committed doses in radioiodine therapy for Graves hyperthyroidism.","volume":"20","author":"Grosso","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"key":"R9-1-20210204","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1687-9856-2011-14","article-title":"Prediction of post-treatment hypothyroidism using changes in thyroid volume after radioactive iodine therapy in adolescent patients with Graves disease.","volume":"2011","author":"Nakatake","year":"2011","journal-title":"Int J Pediatr Endocrinol"},{"key":"R10-1-20210204","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/BF00173482","article-title":"Functional results of radioiodine therapy with a 300-Gy absorbed dose in Graves disease.","volume":"20","author":"Willemsen","year":"1993","journal-title":"Eur J Nucl Med"},{"key":"R11-1-20210204","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1007\/s00259-010-1536-8","article-title":"EANM procedure guidelines for therapy of benign thyroid disease.","volume":"37","author":"Stokkel","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-1-20210204","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1530\/EJE-09-0286","article-title":"Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis.","volume":"161","author":"de Rooij","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"R13-1-20210204","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2362.2008.02061.x","article-title":"Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.","volume":"39","author":"Walter","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"R14-1-20210204","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jc.2002-020805","article-title":"A randomized comparison of radioiodine doses in Graves hyperthyroidism.","volume":"88","author":"Leslie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-1-20210204","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/eje.0.1410117","article-title":"Optimized radioiodine therapy of Graves disease: analysis of the delivered dose and of other possible factors affecting outcome.","volume":"141","author":"Catargi","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"R16-1-20210204","first-page":"1073","article-title":"High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves disease.","volume":"87","author":"Alexander","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-1-20210204","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s00259-006-0234-z","article-title":"Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves disease.","volume":"34","author":"Dunkelmann","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R18-1-20210204","first-page":"387","article-title":"Influence of dose selection on absorbed dose profiles in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole.","volume":"34","author":"Clerc","year":"1993","journal-title":"J Nucl Med"},{"key":"R19-1-20210204","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5603\/NMR.2011.0003","article-title":"The influence of non-radioactive iodine (127I) on the outcome of radioiodine (131I) therapy in patients with Graves disease and toxic nodular goitre.","volume":"14","author":"Rogowski","year":"2011","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"R20-1-20210204","doi-asserted-by":"crossref","first-page":"N81","DOI":"10.1088\/0952-4746\/32\/1\/N81","article-title":"Radiation protection principles.","volume":"32","author":"Cooper","year":"2012","journal-title":"J Radiol Prot"},{"key":"R21-1-20210204","first-page":"1815","article-title":"Four- to twenty-four-hour uptake ratio: an index of rapid iodine-131 turnover in hyperthyroidism.","volume":"37","author":"Aktay","year":"1996","journal-title":"J Nucl Med"},{"key":"R22-1-20210204","first-page":"2","article-title":"The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves disease.","volume":"13","author":"van Isselt","year":"2010","journal-title":"Hell J Nucl Med"},{"key":"R23-1-20210204","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12149-009-0232-x","article-title":"The relationship between 24 h4 h radioiodine-131 uptake ratio and outcome after radioiodine therapy in 1402 patients with solitary autonomously functioning thyroid nodules.","volume":"23","author":"Filesi","year":"2009","journal-title":"Ann Nucl Med"},{"key":"R24-1-20210204","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/10849780260179233","article-title":"Treatment planning for molecular targeted radionuclide therapy.","volume":"17","author":"Siantar","year":"2002","journal-title":"Cancer Biother Radiopharm"},{"key":"R25-1-20210204","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/10849780252824091","article-title":"Options for radionuclide therapy: from fixed activity to patient-specific treatment planning.","volume":"17","author":"Thomas","year":"2002","journal-title":"Cancer Biother Radiopharm"},{"key":"R26-1-20210204","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/cbr.2007.0445","article-title":"Update: the case for patient-specific dosimetry in radionuclide therapy.","volume":"23","author":"Stabin","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"R27-1-20210204","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.2967\/jnumed.111.088666","article-title":"RADAR commentary: evolution and current status of dosimetry in nuclear medicine.","volume":"52","author":"Stabin","year":"2011","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0b013e3182816717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:28:51Z","timestamp":1621884531000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201304000-00001"}},"subtitle":["Thyroid Absorbed Dose of 300 Gy\u2014Tuning the Target for Therapy Planning"],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0b013e3182816717","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}